

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 December 2020 (30.12.2020)



(10) International Publication Number

WO 2020/259584 A1

(51) International Patent Classification:

C07D 403/14 (2006.01) *A61P 11/00* (2006.01)
C07D 403/04 (2006.01) *A61P 17/06* (2006.01)
C07D 239/48 (2006.01) *A61P 25/28* (2006.01)
C07D 487/04 (2006.01) *A61P 27/02* (2006.01)
A61K 31/506 (2006.01) *A61P 35/00* (2006.01)
A61P 1/04 (2006.01) *A61P 37/00* (2006.01)
A61P 3/10 (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2020/098105

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

24 June 2020 (24.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201910572091.9 28 June 2019 (28.06.2019) CN

(71) Applicant: **GUANGZHOU INNOCARE PHARMA TECH CO., LTD.** [CN/CN]; Room 899, No. 333 Jiufu Jianshe Road, Sino-Singapore Guangzhou Knowledge, Guangzhou, Guangdong 510130 (CN).


(72) Inventors: **CHEN, Xiangyang**; Bldg. 8, Community No. 1, No. 8 Courtyard, Life Park Road, ZGC Life Science Park, Changping District, Beijing 102206 (CN). **PANG, Yucheng**; Bldg. 8, Community No. 1, No. 8 Courtyard, Life Park Road, ZGC Life Science Park, Changping District, Beijing 102206 (CN).

(74) Agent: **INTELIGHT IP LAW FIRM**; Suite 1710, Tower B, Techart Plaza, No. 30 Xueyuan Road, Haidian District, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY



(I)

(57) Abstract: Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers.

WO 2020/259584 A1